Invesco
TXG icon

Invesco’s 10x Genomics TXG Stock Holding History

Invesco’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9M Buy
388,512
+70,869
+22% +$1.86M ﹤0.01% 1678
2026
Q1 		$6.74M Sell
317,643
-16,657
-5% -$333K ﹤0.01% 2046
2025
Q4 		$5.45M Buy
334,300
+58,537
+21% +$884K ﹤0.01% 2207
2025
Q3 		$3.22M Buy
275,763
+74,024
+37% +$965K ﹤0.01% 2422
2025
Q2 		$2.34M Buy
201,739
+10,407
+5% +$94.9K ﹤0.01% 2518
2025
Q1 		$1.67M Buy
191,332
+73,265
+62% +$924K ﹤0.01% 2617
2024
Q4 		$1.7M Buy
118,067
+21,134
+22% +$334K ﹤0.01% 2678
2024
Q3 		$2.19M Sell
96,933
-3,485
-3% -$72K ﹤0.01% 2566
2024
Q2 		$1.95M Buy
100,418
+16,607
+20% +$435K ﹤0.01% 2585
2024
Q1 		$3.15M Sell
83,811
-2,251,127
-96% -$98.9M ﹤0.01% 2465
2023
Q4 		$131M Buy
2,334,938
+108,472
+5% +$4.72M 0.03% 680
2023
Q3 		$91.8M Buy
2,226,466
+354,680
+19% +$18.5M 0.02% 747
2023
Q2 		$105M Buy
1,871,786
+204,123
+12% +$11M 0.03% 708
2023
Q1 		$93M Buy
1,667,663
+1,590,355
+2,057% +$74.3M 0.03% 743
2022
Q4 		$2.82M Sell
77,308
-53,570
-41% -$1.75M ﹤0.01% 2505
2022
Q3 		$3.73M Buy
130,878
+2,482
+2% +$94.6K ﹤0.01% 2366
2022
Q2 		$5.81M Sell
128,396
-5,695
-4% -$295K ﹤0.01% 2205
2022
Q1 		$10.2M Sell
134,091
-47,119
-26% -$4.12M ﹤0.01% 1951
2021
Q4 		$27M Sell
181,210
-370,446
-67% -$56.7M 0.01% 1366
2021
Q3 		$80.3M Sell
551,656
-656,798
-54% -$113M 0.02% 879
2021
Q2 		$237M Sell
1,208,454
-94,878
-7% -$17.2M 0.06% 443
2021
Q1 		$236M Buy
1,303,332
+198,217
+18% +$34.2M 0.06% 399
2020
Q4 		$156M Sell
1,105,115
-687,718
-38% -$99.8M 0.05% 537
2020
Q3 		$224M Buy
1,792,833
+478,366
+36% +$50.2M 0.08% 318
2020
Q2 		$117M Buy
1,314,467
+59,445
+5% +$4.63M 0.04% 533
2020
Q1 		$78.2M Buy
1,255,022
+790,769
+170% +$61.7M 0.03% 600
2019
Q4 		$35.4M Buy
464,253
+103,661
+29% +$6.23M 0.01% 1136
2019
Q3 		$18.2M Buy
+360,592
New +$20M ﹤0.01% 1456

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Invesco's TXG Position: Q2 2026 in Review

Invesco increased its 10x Genomics (TXG) stake by 22% in Q2 2026, buying an estimated $1.86M and bringing the position to 388,512 shares worth $14.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1678.

Invesco first reported a position in TXG in Q3 2019 and has held it in 28 quarters since. The position peaked at $237M in Q2 2021. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Invesco held 388,512 shares of 10x Genomics worth $14.9M as of Q2 2026.
  • Invesco bought 70,869 10x Genomics shares in Q2 2026, an estimated $1.86M.
  • 10x Genomics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #1678 holding.
  • Invesco first reported a position in 10x Genomics in Q3 2019 and has held it in 28 quarters since.
  • Invesco's 10x Genomics position peaked at $237M in Q2 2021.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.